Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Asahi Kasei Obtains All Rights Related to Naftopidil from Roche Diagnostics
December 1, 2008
- Groups Present Petition Calling For Ban of Online Sales of Drugs
December 1, 2008
- EPS: CRO Business Props Up 19.2% Growth in Sales
December 1, 2008
- Final Draft GL Published for HRT
December 1, 2008
- BUSINESS NEWS IN BRIEF
December 1, 2008
- SELF-MEDICATION NEWS IN BRIEF
December 1, 2008
- Nichi-Iko to Overtake Taiyo to Become 2nd Largest Generic House, Following Sawai
December 1, 2008
- Pfizer to Perform Study in Japanese Patients to Strengthen Evidence for Selara
December 1, 2008
- Sawai: Sales Up 18% with Good Sales of New Products
December 1, 2008
- Medical Fee System Needs Reform to Deal with High-Cost Drugs: Dr Ishikawa
December 1, 2008
- Taiyo Yakuhin: Sales Up 11.9%
December 1, 2008
- GL on Proper Use of Psychotropics in the Elderly Expected by 2010
December 1, 2008
- Towa: Sales Up 12.8% due to Expansion of Sales to Pharmacies
December 1, 2008
- Standard Regimens for Colon Cancer Used in 56% of Cases
December 1, 2008
- Actavis ASKA Aims at Becoming Leading Generic House in Japan
December 1, 2008
- MEDICAL DEVICE NEWS IN BRIEF
December 1, 2008
- Greater Efforts Needed to Promote Use of Generics: Chuikyo
December 1, 2008
- Kaken: Artz's Sales Up 9.1% Despite NHI Price Cut of 5.8%
November 24, 2008
- Daiichi Sankyo Ties Up with ArQule for Oncology Therapeutics
November 24, 2008
- Kyorin: First Net Loss due to Withdrawal of Gatifloxacin
November 24, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…